1220517-81-6

Basic information

• Product Name: 4-chloro-1-ethyl-6-(Methylthio)-1H-pyrazolo[3,4-d]pyriMidine
• Synonyms: 4-chloro-1-ethyl-6-(Methylthio)-1H-pyrazolo[3,4-d]pyriMidine
• CAS NO: 1220517-81-6
• Molecular Formula: C₈H₉ClN₄S
• Molecular Weight: 228.70186
• Mol File: 1220517-81-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-chloro-1-ethyl-6-(Methylthio)-1H-pyrazolo[3,4-d]pyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-1-ethyl-6-(Methylthio)-1H-pyrazolo[3,4-d]pyriMidine(1220517-81-6)
• EPA Substance Registry System: 4-chloro-1-ethyl-6-(Methylthio)-1H-pyrazolo[3,4-d]pyriMidine(1220517-81-6)

Safety Data

• Hazardous Substances Data: 1220517-81-6(Hazardous Substances Data)

Upstream product

• 85426-79-5 4-chloro-6-methylmercapto-1H-pyrazolo[3,4-d]pyrimidine 
• 75-03-6 ethyl iodide 
• 33097-11-9 4,6-dichloro-2-methylsulfanylpyrimidine-5-carboxyaldehyde 
• 1979-98-2 4,6-dihydroxy-2-methylmercaptopyrimidine 
• 6629-60-3 ethylhydrazine oxalic acid salt 

Downstream Products

• 1220517-82-7 4-chloro-1-ethyl-6-(methylsulfonyl)-1H-pyrazolo[3,4-d]pyrimidine 

Relevant articles and documents

NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING

New pyrimidine derivatives together with a membrane penetrating agent, optionally with a detectable isotope and pharmaceutical composition for use in treatment or prevention of Gram-negative bacterial infection in a host mammal in need of such treatment or prevention and use as inhibitors of Gram-negative biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers. New pyrimidine derivatives together with a membrane penetrating agent; for use as radiotracer in diagnosing or prognosing Gram-negative bacterial infection in a host mammal.

HETEROCYCLIC JAK KINASE INHIBITORS

The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer